Preclinical News and Research

RSS

Sinovac third quarter sales decrease 7% to $9.6 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the three-month and nine-month periods ended September 30, 2010.

15 Nov 2010

Inovio third quarter total revenue decreases from $3.6 million to $1.3 million

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2010.

15 Nov 2010

Cerulean closes $24 million Series C financing by Lilly Ventures

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that the Company has closed a $24 million Series C financing led by Lilly Ventures, with participation from all other existing investors including Polaris Venture Partners, Venrock, Lux Capital, and Bessemer Venture Partners.

15 Nov 2010

ICON, Proteome enter alliance to provide expanded biomarker solutions

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and Proteome Sciences a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of a strategic alliance to provide pharmaceutical companies with an expanded biomarker solution to allow earlier assessments in the development of new medicines.

15 Nov 2010

Biodel reports data on Linjeta formulation for type 1 diabetes at Technology Meeting in Bethesda

Scientists from Biodel Inc. reported new findings from the company's Linjeta, insulin glargine, "smart" basal insulin and stabilized glucagon development programs in poster presentations yesterday and today at the Tenth Annual Diabetes Technology Meeting in Bethesda, MD.

15 Nov 2010

TCA Cellular Therapy receives QTDP grant for adult stem cell therapies

TCA Cellular Therapy was recently awarded a Qualifying Therapeutic Discovery Program (QTDP) grant from U.S. Department of Health and Human Services. The program was highly competitive with nearly seven thousand applicants vying for funding.

14 Nov 2010

Amorfix second quarter net loss decreases to $25,728

Amorfix Life Sciences, a product development company focused on the development of diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the three and six months ended September 30, 2010.

12 Nov 2010

CytomX awarded $488,000 as grant under QTDP Program

CytomX Therapeutics, a biotechnology company focused on the development of proteolytically activated antibodies, today announced the receipt of two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The grants are directed toward the company's lead preclinical programs targeting colon, head and neck, pancreatic and triple-negative breast cancers and glioblastoma multiforme (GBM).

12 Nov 2010

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the third quarter and the nine months ended September 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.

12 Nov 2010

NovaBay third quarter net loss increases to $1.6 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has reported third quarter financial results and highlighted the clinical progress of its in-house programs.

12 Nov 2010

Archives of Physical Medicine and Rehabilitation publishes articles on TBI

The November 2010 issue of the Archives of Physical Medicine and Rehabilitation, Official Journal of the American Congress of Rehabilitation Medicine, has published a set of 9 articles on traumatic brain injury (TBI) that will accelerate future research in the field by establishing common language for the degree of injury, how it is measured and classified, treatment and potential outcomes.

12 Nov 2010

Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference

Reata Pharmaceuticals today announced that the company will present data on the primary endpoint from a pivotal Phase 2b clinical trial of bardoxolone methyl in patients with chronic kidney disease (CKD) and type 2 diabetes. The data will be presented in a late-breaking oral presentation at the American Society of Nephrology (ASN) Renal Week Conference to be held November 16-21, 2010, in Denver, Colorado.

12 Nov 2010

Acetylon receives two grants under QTDP program to advance HDAC6 inhibitor drug candidate

Acetylon Pharmaceuticals, Inc. today announced that it has been awarded two grants totaling $488,000 under the Qualifying Therapeutic Discovery Project (QTDP) program.

12 Nov 2010

NIH/NIDCR awards $1.1 million grant to Agenta for soft tissue healing development

Agenta Biotechnologies, Inc., a private biotechnology company, announced that it has received a $1.1 million grant from the National Institutes of Health and National Institute of Dental and Craniofacial Research (NIH/NIDCR) for the further development of a biologically activated membrane to improve soft tissue healing associated with oral surgery.

12 Nov 2010

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

NephRx Corporation today announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure, is in development for the prevention of delayed graft function (DGF) in kidney transplantation patients.

11 Nov 2010

Evotec revenues increase 33% to € 38.8 m during first nine months of 2010

Evotec AG today reported financial results and a corporate update for the first nine months of 2010.

11 Nov 2010

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today publication of data demonstrating that its sapacitabine oral nucleoside analog works synergistically with histone deacetylase (HDAC) inhibitors to induce significant reductions in tumor cell growth in both in vitro and in vivo preclinical models.

11 Nov 2010

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Cortex Pharmaceuticals, Inc. announced that it had been notified by Les Laboratoires Servier ("Servier"), France's largest privately held pharmaceutical company, of their intent to move forward into Phase I clinical studies with the jointly-discovered High Impact AMPAKINE® compound S47445 (CX1632).

11 Nov 2010

Exhausted neurons die prematurely and trigger disease symptoms

We all know that living a stressful lifestyle can take its toll, making us age faster and making us more susceptible to the cold going around the office.

11 Nov 2010

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Hygeia Therapeutics, Inc. announced today the successful completion of a series of preclinical studies for HYG-102, their lead product for the treatment of vulvar and vaginal atrophy (VVA) and age-related skin fragility. HYG-102 is the lead biodegradable estrogenic candidate in a portfolio of 23 similar compounds licensed from the laboratory of Dr. Richard Hochberg of Yale University.

11 Nov 2010

Preclinical News and Research

Sinovac third quarter sales decrease 7% to $9.6 million

Inovio third quarter total revenue decreases from $3.6 million to $1.3 million

Cerulean closes $24 million Series C financing by Lilly Ventures

ICON, Proteome enter alliance to provide expanded biomarker solutions

Biodel reports data on Linjeta formulation for type 1 diabetes at Technology Meeting in Bethesda

TCA Cellular Therapy receives QTDP grant for adult stem cell therapies

Amorfix second quarter net loss decreases to $25,728

CytomX awarded $488,000 as grant under QTDP Program

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

NovaBay third quarter net loss increases to $1.6 million

Archives of Physical Medicine and Rehabilitation publishes articles on TBI

Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference

Acetylon receives two grants under QTDP program to advance HDAC6 inhibitor drug candidate

NIH/NIDCR awards $1.1 million grant to Agenta for soft tissue healing development

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

Evotec revenues increase 33% to € 38.8 m during first nine months of 2010

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Exhausted neurons die prematurely and trigger disease symptoms

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics